This development is part of Botanix’s strategy to expand payer coverage, now reaching over 110 million commercial lives, for its novel treatment targeting primary axillary hyperhidrosis, a condition ...

Specialists rely on the hyperhidrosis severity scale to assess the seriousness of the situation, as well as the discomfort in order to find an appropriate treatment. Treatments to consider The first ...

Cold sores, sore throats, migraines and conjunctivitis are among the conditions which will no longer be treated on the NHS by ...

Complete enrollment in its DMT310 Phase 3 STAR-1 clinical trial in moderate-to-severe acne. Dermata expects to complete enrollment in the STAR-1 study by the end of 2024 and plans to announce topline ...